News Sentiment

CADL sentiment intelligence

Candel Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.49 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-3.5% over one week, +10.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -3.5% Price reacting lower
Trend fit Trend active 10.9% over four weeks
Fair value 83.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 37
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 17
Market source 8
TradingView 6
Investing.com 4
simplywall.st 4
Stocktwits 3
GlobeNewswire 2
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 11
Analyst action 5
Balance sheet 3
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Stock Traders Daily Direct company coverage

Liquidity Mapping Around (CADL) Price Events

This article provides an AI-generated analysis of Candel Therapeutics Inc. (NASDAQ: CADL) price events, highlighting weak near-term sentiment with potential shifts in mid and long-term outlook. It details specific institutional trading strategies (Position, Momentum Breakout, and

Tone
Neutral 50/100
Event
Guidance
Published
13 Jul 2026 18:56
Source
Stock Traders Daily
Investing.com Direct company coverage

Stifel initiates Candel Therapeutics stock with buy, $22 target

Stifel initiated coverage on Candel Therapeutics Inc. (NASDAQ:CADL) with a Buy rating and a $22.00 price target, significantly higher than its current stock price. The firm's positive outlook is based on the company's aglatimagene therapy, a clinically validated viral immunothera

Tone
Positive 73/100
Event
Analyst action
Published
13 Jul 2026 14:12
Source
Investing.com
GuruFocus Direct company coverage

CADL Initiates Coverage On Candel Therapeutics by Stifel -- Buy Rating Issued

Stifel analyst Stephen Willey has initiated coverage on Candel Therapeutics (CADL) with a "Buy" rating and a price target of $22.00, significantly above its current trading price of $9.47. Despite this optimistic outlook, Candel Therapeutics holds a low GF Score™ of 25/100, indic

Tone
Positive 65/100
Event
Analyst action
Published
13 Jul 2026 10:41
Source
GuruFocus
Stock Titan Direct company coverage

Candel hands its new commercial chief 285,000 options

Candel Therapeutics (Nasdaq: CADL) announced that it granted 285,000 stock options to its new Chief Commercial Officer, Mark Sims, under Nasdaq Listing Rule 5635(c)(4) and the company's 2025 Inducement Plan. The options have an exercise price of $10.03, matching the Nasdaq closin

Tone
Positive 63/100
Event
Market update
Published
09 Jul 2026 00:13
Source
Stock Titan
Stock Titan Direct company coverage

Candel Therapeutics (CADL) Chief Commercial Officer Sims listed in Form 3

Candel Therapeutics, Inc. (CADL) filed a Form 3 to list Mark E. Sims as its Chief Commercial Officer. This initial statement of beneficial ownership indicates no share transactions or holdings for Sims, with zero reported purchases or sales. The filing serves to establish Sims's

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Candel Therapeutics, Inc. Insider Trading Activity

Candel Therapeutics, Inc.'s Chief Commercial Officer, Mark E. Sims, was granted 285,000 stock options with an exercise price of $10.03 per share, expiring on July 6, 2036. The options will vest 25% on July 6, 2027, with the remainder vesting in 36 equal monthly installments, cont

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:40
Source
Stock Titan
GlobeNewswire Direct company coverage

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics announced the grant of stock options to Mark Sims, its new Chief Commercial Officer, as an inducement for his employment. The grant, totaling 285,000 shares with an exercise price of $10.03, was made on July 6, 2026, under the Company's 2025 Inducement Plan. T

Tone
Positive 63/100
Event
Market update
Published
08 Jul 2026 16:05
Source
GlobeNewswire
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO)

Two healthcare companies, Candel Therapeutics (CADL) and Ibio (IBIO), have received bullish sentiments from analysts. Citi analyst Yigal Nochomovitz maintained a Buy rating on Candel Therapeutics with a $26.00 price target, while Keay Nakae from Chardan Capital reiterated a Buy r

Tone
Positive 86/100
Event
Analyst action
Published
03 Jul 2026 10:40
Source
The Globe and Mail
Stock Titan Direct company coverage

Candel Therapeutics (CADL) director receives fully vested 381-option equity grant

Candel Therapeutics director Nicoletta Loggia received a fully vested grant of 381 stock options with an exercise price of $10.30 per share, expiring on June 30, 2036. This grant was issued as compensation in lieu of normal quarterly cash payments. Following this transaction, Log

Tone
Neutral 50/100
Event
Balance sheet
Published
01 Jul 2026 22:10
Source
Stock Titan
Investing.com Direct company coverage

Candel Therapeutics CSO Francesca Barone sells $235k in stock

Francesca Barone, Chief Scientific Officer of Candel Therapeutics, Inc. (NASDAQ:CADL), sold 23,447 shares of company stock for approximately $235,768 on June 29, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan. The sale followed a period of strong stock perf

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:09
Source
Investing.com
Investing.com Canada Direct company coverage

Form 4 Candel Therapeutics Inc For: 1 July By Investing.com

This article announces a Form 4 filing for Candel Therapeutics Inc. for July 1st. It also includes various market data, trending stocks, and popular news articles from Investing.com, along with promotions for their investing tools.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:40
Source
Investing.com Canada
Stock Titan Direct company coverage

Candel Therapeutics (CADL) director receives fully vested grant of 2,199 stock options

Candel Therapeutics director Paul B. Manning received a grant of 2,199 stock options as compensation, which are fully vested upon grant and replace normal quarterly cash payments. These options allow him to purchase shares at an exercise price of $10.30 per share. This transactio

Tone
Neutral 50/100
Event
Balance sheet
Published
01 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Candel Therapeutics (CADL) director receives fully vested option award

Candel Therapeutics director Joseph C. Papa received a fully vested stock option award of 1,331 options to purchase common stock at an exercise price of $10.30 per share. This grant was issued in lieu of regular quarterly cash payments and is immediately exercisable, allowing him

Tone
Neutral 50/100
Event
Balance sheet
Published
01 Jul 2026 20:40
Source
Stock Titan
The Manila Times Direct company coverage

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics announced the grant of inducement stock options to a new employee for 25,000 shares of common stock at an exercise price of $10.30 per share. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment and will vest

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
The Manila Times
Stock Titan Direct company coverage

Candel grants new employee 25,000 stock options at $10.30

Candel Therapeutics (CADL) has granted 25,000 inducement stock options to a new employee at an exercise price of $10.30 per share. This award, under the company's 2025 Inducement Plan, vests 25% after one year and the remaining 75% over 36 monthly installments, contingent on cont

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:40
Source
Stock Titan
Investing.com Direct company coverage

Candel Therapeutics initiates phase 3 lung cancer trial

Candel Therapeutics (NASDAQ:CADL) has launched its global phase 3 AURORA trial for metastatic non-squamous non-small cell lung cancer, combining aglatimagene besadenovec plus valacyclovir with pembrolizumab. This follows a successful phase 2 trial and Fast Track Designation from

Tone
Positive 70/100
Event
Market update
Published
01 Jul 2026 10:13
Source
Investing.com
TradingView Direct company coverage

Price to earnings forward of Candel Therapeutics, Inc. – NASDAQ:CADL

This page from TradingView provides financial information for Candel Therapeutics, Inc. (NASDAQ: CADL), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of viewing, with no trades executed.

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 00:13
Source
TradingView
Investing.com South Africa Direct company coverage

Candel Therapeutics initiates phase 3 lung cancer trial By Investing.com

Candel Therapeutics (NASDAQ:CADL) has launched its global phase 3 AURORA trial for metastatic non-squamous non-small cell lung cancer, combining aglatimagene besadenovec with valacyclovir and pembrolizumab. The stock surged 83% in six months, nearing its 52-week high, reflecting

Tone
Positive 73/100
Event
Market update
Published
30 Jun 2026 17:11
Source
Investing.com South Africa
Stock Titan Direct company coverage

Candel opens global phase 3 AURORA trial in lung cancer

Candel Therapeutics has initiated the global pivotal phase 3 AURORA trial for aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer (NSCLC) patients who progressed after immune checkpoint inhibitors and chemotherapy. The trial aims to assess overall survival,

Tone
Positive 74/100
Event
Market update
Published
30 Jun 2026 12:11
Source
Stock Titan
The Manila Times Direct company coverage

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Candel Therapeutics has initiated its global pivotal Phase 3 AURORA trial for aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer (NSCLC) patients who show an inadequate response to immune checkpoint inhibitors. The trial will compare CAN-2409 in combinatio

Tone
Positive 71/100
Event
Market update
Published
30 Jun 2026 12:11
Source
The Manila Times
Stock Titan Direct company coverage

Candel Therapeutics, Inc. SEC Filing

This article reports on a Form 144 SEC filing by Candel Therapeutics, Inc. (CADL) on June 29, 2026, which is categorized as neutral in impact and sentiment. The filing details the proposed sale of 7,000 common shares with an aggregate market value of $68,530.00, acquired on Janua

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:44
Source
Stock Titan
PMLiVE Direct company coverage

Candel Therapeutics appoints Mark Sims as Chief Commercial Officer

Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective July 6, 2026. Sims, with 25 years of oncology commercial experience from AstraZeneca, Novartis, and Merck, will lead the commercial strategy and launch readiness for aglatimagene besadenovec (CAN-2

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 12:09
Source
PMLiVE
TradingView Direct company coverage

Price to sales forward of Candel Therapeutics, Inc. – NASDAQ:CADL

This article displays the "Price to sales forward" metric for Candel Therapeutics, Inc. (NASDAQ: CADL). It is a brief financial data point from TradingView, which provides market and reference data from ICE Data Services and FactSet Research Systems Inc. The content itself is ver

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 03:39
Source
TradingView
TradingView Direct company coverage

Candel Therapeutics, Inc. Actuals & Estimates (NASDAQ:CADL)

This article provides an overview of Candel Therapeutics, Inc. (NASDAQ: CADL) stock, including its current price, historical performance, analyst forecasts, and key financial data. It highlights the company's strong stock performance over the past year, with a 96.59% increase, an

Tone
Positive 71/100
Event
Analyst action
Published
26 Jun 2026 21:39
Source
TradingView